205 related articles for article (PubMed ID: 17033262)
21. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements.
Arlt W; Rosenthal C; Hahner S; Allolio B
Clin Endocrinol (Oxf); 2006 Apr; 64(4):384-9. PubMed ID: 16584509
[TBL] [Abstract][Full Text] [Related]
22. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes.
Riedel M; Wiese A; Schürmeyer TH; Brabant G
Exp Clin Endocrinol; 1993; 101(2):106-11. PubMed ID: 8405139
[TBL] [Abstract][Full Text] [Related]
23. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy.
Björnsdottir S; Øksnes M; Isaksson M; Methlie P; Nilsen RM; Hustad S; Kämpe O; Hulting AL; Husebye ES; Løvås K; Nyström T; Bensing S
Clin Endocrinol (Oxf); 2015 Jul; 83(1):28-35. PubMed ID: 25400085
[TBL] [Abstract][Full Text] [Related]
24. Steroid replacement in Addison's disease and in subjects adrenalectomized for Cushing's disease: comparison of various glucocorticoids.
Khalid BA; Burke CW; Hurley DM; Funder JW; Stockigt JR
J Clin Endocrinol Metab; 1982 Sep; 55(3):551-9. PubMed ID: 6284785
[No Abstract] [Full Text] [Related]
25. Validation of an LC-MS/MS salivary assay for glucocorticoid status assessment: Evaluation of the diurnal fluctuation of cortisol and cortisone and of their association within and between serum and saliva.
Mezzullo M; Fanelli F; Fazzini A; Gambineri A; Vicennati V; Di Dalmazi G; Pelusi C; Mazza R; Pagotto U; Pasquali R
J Steroid Biochem Mol Biol; 2016 Oct; 163():103-12. PubMed ID: 27108942
[TBL] [Abstract][Full Text] [Related]
26. Subjective health status in Norwegian patients with Addison's disease.
Løvås K; Loge JH; Husebye ES
Clin Endocrinol (Oxf); 2002 May; 56(5):581-8. PubMed ID: 12030907
[TBL] [Abstract][Full Text] [Related]
27. GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal.
Martins MR; Pinto AC; Brunner E; Silva MR; Lengyel AM
J Endocrinol Invest; 2003 Feb; 26(2):143-7. PubMed ID: 12739742
[TBL] [Abstract][Full Text] [Related]
28. Plasma, salivary and urinary cortisol levels following physiological and stress doses of hydrocortisone in normal volunteers.
Jung C; Greco S; Nguyen HH; Ho JT; Lewis JG; Torpy DJ; Inder WJ
BMC Endocr Disord; 2014 Nov; 14():91. PubMed ID: 25425285
[TBL] [Abstract][Full Text] [Related]
29. Acute changes in serum thyrotrophin in treated Addison's disease.
Ismail AA; Burr WA; Walker PL
Clin Endocrinol (Oxf); 1989 Mar; 30(3):225-30. PubMed ID: 2591055
[TBL] [Abstract][Full Text] [Related]
30. Replacement therapy in Addison's disease.
Løvås K; Husebye ES
Expert Opin Pharmacother; 2003 Dec; 4(12):2145-9. PubMed ID: 14640913
[TBL] [Abstract][Full Text] [Related]
31. Cortisol and cortisone acetate in parenteral glucocorticoid therapy?
Kehlet H; Madsen SN; Binder C
Acta Med Scand; 1974 May; 195(5):421-3. PubMed ID: 4830060
[No Abstract] [Full Text] [Related]
32. GDF15 Is Elevated in Conditions of Glucocorticoid Deficiency and Is Modulated by Glucocorticoid Replacement.
Melvin A; Chantzichristos D; Kyle CJ; Mackenzie SD; Walker BR; Johannsson G; Stimson RH; O'Rahilly S
J Clin Endocrinol Metab; 2020 May; 105(5):1427-34. PubMed ID: 31853550
[TBL] [Abstract][Full Text] [Related]
33. Saliva and bloodspot cortisol: novel sampling methods to assess hydrocortisone replacement therapy in hypoadrenal patients.
Wong V; Yan T; Donald A; McLean M
Clin Endocrinol (Oxf); 2004 Jul; 61(1):131-7. PubMed ID: 15212655
[TBL] [Abstract][Full Text] [Related]
34. Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proof-of-concept study.
Ceccato F; Barbot M; Lizzul L; Selmin E; Saller A; Albiger N; Betterle C; Boscaro M; Scaroni C
Clin Endocrinol (Oxf); 2018 Feb; 88(2):201-208. PubMed ID: 28973827
[TBL] [Abstract][Full Text] [Related]
35. Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease.
Cohen N; Gilbert R; Wirth A; Casley D; Jerums G
J Clin Endocrinol Metab; 1996 Apr; 81(4):1411-5. PubMed ID: 8636343
[TBL] [Abstract][Full Text] [Related]
36. Acutely raised corticotropin levels in Addison's disease are not associated with increased plasma arginine vasopressin and corticotropin-releasing factor concentrations in peripheral plasma.
Wittert GA; Livesey JH; Florkowski C; Or HK; Donald RA; Espiner EA
J Clin Endocrinol Metab; 1993 Jan; 76(1):192-6. PubMed ID: 8380605
[TBL] [Abstract][Full Text] [Related]
37. Salivary cortisol and cortisone in the clinical setting.
Blair J; Adaway J; Keevil B; Ross R
Curr Opin Endocrinol Diabetes Obes; 2017 Jun; 24(3):161-168. PubMed ID: 28375882
[TBL] [Abstract][Full Text] [Related]
38. Oedema in patients with Addison's disease on replacement therapy: glucocorticoid excess and mineralocorticoid deficiency?
Flynn MD; Shore AC; Sandeman DE; Mawson D; Donohoe M; Tooke JE
QJM; 1994 Jul; 87(7):437-41. PubMed ID: 7922296
[TBL] [Abstract][Full Text] [Related]
39. Mineralocorticoid replacement in Addison's disease.
Thompson DG; Mason AS; Goodwin FJ
Clin Endocrinol (Oxf); 1979 May; 10(5):499-506. PubMed ID: 476980
[TBL] [Abstract][Full Text] [Related]
40. Urine free-cortisol determination. A useful tool in the management of chronic hypoadrenal states.
Burch WM
JAMA; 1982 Apr; 247(14):2002-4. PubMed ID: 7062507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
